X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
HOPO 14-1 (3,4,3-Li(1,2-hopo) is a novel orally administered experimental drug, designed to act as a defence against radioactive threats and is being investigated to treat radioactive contamination in the body.
Lead Product(s): 3,4,3-Li(1,2-hopo)
Therapeutic Area: Pharmacology/Toxicology Product Name: HOPO 14-1
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2023
Details:
Under the terms of the agreement, the organizations and their scientists will leverage SRI’s SynFini™ platform, an artificial intelligence (Al)-guided, automated synthetic- chemistry system for small molecule drug discovery.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 05, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
